Title

Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle

UMMS Affiliation

Department of Radiology, Division of Nuclear Medicine

Date

4-1-2010

Document Type

Article

Medical Subject Headings

Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chromatography, Gel; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Dose-Response Relationship, Radiation; Drug Delivery Systems; Female; Humans; Iodine Radioisotopes; Morpholines; Morpholinos; Nanoparticles; Oligonucleotides, Antisense; Streptavidin; Tumor Stem Cell Assay

Disciplines

Nanomedicine | Neoplasms | Radiology | Therapeutics

Abstract

We reported recently that a three-component nanoparticle, consisting of a targeting antibody, a transfecting peptide and an 111In-antiRIalpha MORF antisense oligomer, provided Auger electron-mediated, antisense-mediated, cytotoxicity of cells in culture. We have now measured the cytotoxicity of the nanoparticle in culture with the 111In replaced by 125I, another attractive Auger electron emitter. The nanoparticle consisted of streptavidin linking the 125I labeled antiRIalpha mRNA antisense MORF oligomer, the tat transfecting peptide and the anti-Her2 Trastuzumab antibody. Cytotoxicity was evaluated by a clonogenic survival assay in BT-474 (Her2+) human breast cancer cells. In a dose escalation study, as measured by the surviving fraction, the cytotoxicity of tumor cells to the 125I-labeled antisense nanoparticle was significantly higher than that for the identical sense control. When compared with our previous study with 111In as label, a similar level of cytotoxicity was achieved but the observed minimal therapeutic dose for the 125I-labeled nanoparticle in BT-474 cells was lower than that for 111In-labeled nanoparticle in SK-BR-3 cells. Thus, a radiolabeled antisense MORF oligomer delivered into cells by a three-component nanoparticle is an effective vehicle for Auger radiotherapy when radiolabeled with 111In or 125I.

Rights and Permissions

Citation: J Biomed Nanotechnol. 2010 Apr;6(2):153-7. doi:10.1166/jbn.2010.1111

Related Resources

Link to Article in PubMed

PubMed ID

20738069